HGH Fragment 176-191

HGH Fragment 176-191 is a stabilized analog of the lipolytic region of human growth hormone. This C-terminal fragment retains the fat-metabolizing effects of hGH without growth-promoting or diabetogenic properties.

Mechanism of Action

HGH Fragment 176-191 (also known as AOD9604) specifically activates lipolysis in adipose tissue without affecting blood glucose or IGF-1 levels. Both hGH and its C-terminal fragment reduce body weight gain, increase fat oxidation, and stimulate lipolysis in obese mice, yet AOD9604 does not interact with the hGH receptor or induce hyperglycemia (Heffernan et al., 2001). The fragment targets fat metabolism pathways by increasing beta(3)-adrenergic receptor expression without the broader effects of full-length growth hormone (Heffernan et al., 2001).

Research Applications

• Selective fat metabolism studies (Heffernan et al., 2001)
• Lipolysis mechanisms (Heffernan et al., 2001)
• Obesity research without GH side effects
• Adipocyte biology
• Body composition studies

Product Specifications

• Purity: ≥99% (HPLC verified)
• Molecular Weight: 1817.1 Da
• Form: Lyophilized powder
• Storage: -20°C

References

1. Heffernan MA, et al. "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment." Int J Obes Relat Metab Disord. 2001. PMID: 11673763
2. Heffernan MA, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001. PMID: 11713213